Canton Strategic Holdings (CNTN) Interest & Investment Income (2023 - 2026)
Canton Strategic Holdings (CNTN) reported Interest & Investment Income of $318178.0 for Q1 2026, up 2268.1% on a YoY basis from $13436.0 in Q1 2025, and up 1203.05% quarter-over-quarter from $24418.0 in Q4 2025.
Canton Strategic Holdings (CNTN) Interest & Investment Income (2023 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Interest & Investment Income for 4 years, with the latest figure at $318178.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 2268.1% year-over-year to $318178.0; the trailing twelve-month figure through Mar 2026 stood at $346152.0 (up 106.72% YoY), and the FY2025 full-year result was $41410.0, down 83.43% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $318178.0, up from $24418.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $318178.0 in Q1 2026, with the low at $1388.0 in Q3 2025.
- Historically, Interest & Investment Income has averaged $58625.2 across 4 years, with a median of $32248.0 in 2023.
- Annual changes were most pronounced in 2025 — Interest & Investment Income plunged 98.09% — and 2026, when it jumped 2268.1%.
- Canton Strategic Holdings' Interest & Investment Income stood at $57733.0 in 2023, then slumped by 52.07% to $27672.0 in 2024, then dropped by 11.76% to $24418.0 in 2025, then soared by 1203.05% to $318178.0 in 2026.
- The last three Interest & Investment Income figures came in at $318178.0 (Q1 2026), $24418.0 (Q4 2025), and $1388.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 318,178.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 318,178.00 |
| Dec 31, 2025 | 24,418.00 |
| Sep 30, 2025 | 1,388.00 |
| Jun 30, 2025 | 2,168.00 |
| Mar 31, 2025 | 13,436.00 |
| Dec 31, 2024 | 27,672.00 |
| Sep 30, 2024 | 72,728.00 |
| Jun 30, 2024 | 53,614.00 |
| Mar 31, 2024 | 95,894.00 |
| Dec 31, 2023 | 57,733.00 |
| Sep 30, 2023 | 28,451.00 |
| Jun 30, 2023 | 34,199.00 |
| Mar 31, 2023 | 32,248.00 |